ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
Endocrine Abstracts · 04.03.2026
DOI: 10.1530/endoabs.116.t15 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Abstracts, online erschienen am 04.03.2026. Verfasst von Aman Chauhan und 19 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Chauhan, A., Konda, B., Weiss, H., Soares, H., Li, D., Yao, J., Bowen, B. A., Popa, E., Hitchcock, K., Deek, M., Lubner, S., Kim, E., Zhang, J., Kunos, C., Ivy, P., Gore, S., Pelosof,, L., Kohn, E., Arnold, S., & Anthony, L. (2026). ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors. Endocrine Abstracts. https://doi.org/10.1530/endoabs.116.t15
Vancouver
Chauhan A, Konda B, Weiss H, Soares H, Li D, Yao J, et al. ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors. Endocrine Abstracts. 2026. doi:10.1530/endoabs.116.t15
BibTeX
@article{Chauhan2026,
author = {Chauhan, Aman and Konda, Bhavana and Weiss, Heidi and Soares, Heloisa and Li, Daneng and Yao, James and Bowen, Benson Al and Popa, Elizabeth and Hitchcock, Katherine and Deek, Matthew and Lubner, Sam and Kim, Edward and Zhang, Janie and Kunos, Charles and Ivy, Percy and Gore, Steven and Pelosof,, Lorraine and Kohn, Elise and Arnold, Susanne and Anthony, Lowell},
title = {ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors},
journal = {Endocrine Abstracts},
year = {2026},
doi = {10.1530/endoabs.116.t15}
}
EUVIMED